Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Progress with Kraft Foods Partnership

23rd Dec 2008 07:00

RNS Number : 6512K
TyraTech, Inc.
23 December 2008
 



For Immediate Release

23 December 2008

TYRATECH, INC.

("TyraTech" or "the Company")

Kraft Foods Partnership Progress and Early Milestone Payment

~ Revised agreement completed as project successfully advances~

TyraTech, Inc. (AIM: TYR), a leading independent novel clean technology company for human, animal and environmental health, is pleased to announce that it has amended its worldwide exclusive co-development and technology sub-license agreement ("Agreement") originally signed in December 2006 with Kraft Foods Inc ("Kraft", NYSE: KFT), the world's second largest food company with annual revenues of approximately $40 billion and sales in more than 150 countries.  The innovative collaboration was formed to develop new, functional-food products to benefit people living in areas with endemic parasitic disease. Under the revised terms of the Agreement, Kraft has paid more than 75% of a significant project milestone payment ahead of schedule based in part on successful data and progress with the programme. The value of the stage two payment is undisclosed.

The original Agreement defined sequential project milestones relating to progress made by both parties. The Agreement included significant milestone payments made to TyraTech upon successful completion of work in each of four defined stages, along with the ability of Kraft to later recover certain development costs from royalties due under the agreement. TyraTech and Kraft successfully completed Stage One in December 2007, following positive preclinical efficacy data of the TyraTech Natural compounds, and TyraTech received its first milestone payment.

Work for the second stage has been actively progressing and is expected to be completed in 2009. Successful accomplishment of key project objectives in 2008 has allowed for some modifications to the Agreement to be made. Under the terms of the revised Agreement Kraft accelerated payment of more than 75% of the stage two milestone to TyraTech in December 2008. In return, Kraft will benefit from a modified royalty payment schedule to accelerate Kraft's recovery of the Agreement specified development costs when the product is released into the market.

Both companies continue to work aggressively on the project and expect the entire stage two phase to be completed in 2009. At that time, the balance of the stage two milestone payment would be made by Kraft to TyraTech.

Commenting on the announcement, Douglas Armstrong Ph.D., Chief Executive Officer of TyraTech, said: "The revised Agreement is a direct result of the exciting progress and success that TyraTech is having in its partnership with Kraft. The acceleration of the milestone cash payment is an important endorsement by Kraft of our TyraTech Natural technology, and provides useful working capital for TyraTech. These events should be an exciting sign for our shareholders of the ongoing progress at TyraTech."

For further information please contact:

TyraTech Inc.

Douglas Armstrong Ph.D., Chief Executive Officer +1 (321) 409 7403

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Charles Walker +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

MaryߛJane Johnson / Lisa Baderoon +44 (0)20 7466 5000 / Catherine Breen / Stasa Filiplic

About TyraTech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company’s proprietary technology. TyraTech, which already has a product on the market, is positioned for human health, animal health and pesticide market opportunities which total over $23 billion globally. TyraTech’s technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech’s platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

TyraTech's plan for the use of its technology is to develop selected proprietary active ingredients which can then be used across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, and for an insect/mosquito repellent. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.

TyraTech also has a separate technology with associated intellectual property that is the basis for the Sustainable Solutions business. This technology has been incorporated into specialised dairy farm equipment for processing cattle manure waste to a usable material for TyraTech to sell as a commercial plant growing medium. For more information please visit www.tyratech.com.

About the Agreement with Kraft

In December 2006, TyraTech signed a worldwide exclusive co-development agreement with Kraft Foods Inc ("Kraft", NYSE: KFT), the world's second largest food company with annual revenues of approximately $40 billion and sales in more than 150 countries . The agreement covers parasitic prevention applications of TyraTech technology to be delivered in food products. With an active development program in place, Kraft and TyraTech are moving to advance both the technical validation and lead market qualification process. 

The agreement includes exclusivity fees, milestone payments and royalties. The first exclusivity payment was received in 2006 and represented a significant commitment by Kraft. The first milestone payment was received in December 2007 following completion of the designated activities and subsequent milestones were determined at that time. This partnership represents not only a novel technological solution to the vast problem of human parasitic infestation (over 2 billion infested), but by using food also utilises a unique business channel that can reach the affected populations. 

While therapeutic options for treatment of intestinal parasites exist, many of them have major problems due to the toxicity of the treatments and they therefore cannot be used frequently enough to prevent re-infestation. The TyraTech prophylactic approach however, is designed to be safe enough to use in food every day. This not only opens a distribution channel more readily available to the developing world customer, but also greatly expands the size of the market.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUUUARWORUUUA

Related Shares:

Tyratech
FTSE 100 Latest
Value8,809.74
Change53.53